Compare SBFM & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBFM | NVNO |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | United States | United States |
| Employees | N/A | 37 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 7.2M |
| IPO Year | N/A | N/A |
| Metric | SBFM | NVNO |
|---|---|---|
| Price | $1.10 | $10.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 31.0K | 13.3K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.26 | N/A |
| Revenue Next Year | $32.63 | $140.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.30 |
| 52 Week High | $2.43 | $12.85 |
| Indicator | SBFM | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 49.86 |
| Support Level | N/A | $9.76 |
| Resistance Level | $1.52 | $12.69 |
| Average True Range (ATR) | 0.04 | 0.90 |
| MACD | 0.00 | -0.21 |
| Stochastic Oscillator | 26.77 | 30.31 |
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.